Adjuvant zoledronic acid therapy for patients with early stage breast cancer: An updated systematic review and meta-analysis

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  He, Mingfeng ^a   Fan, Weidong ^a   Zhang, Xianquan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Adjuvant; Bisphosphonates; Breast cancer; Meta analysis; Zoledronic acid

Indexed keywords

ANASTROZOLE; GOSERELIN; LETROZOLE; TAMOXIFEN; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; HUMAN; META ANALYSIS; REVIEW; SYSTEMATIC REVIEW;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES;

EID: 84885988024     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-80     Document Type: Review

References (35)

1. Cancer statistics, 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
2. The clinical course of bone metastases from breast cancer. Coleman RE, Rubens RD, Br J Cancer 1987 55 61 66 10.1038/bjc.1987.13 3814476 (Pubitemid 17234155)
3. Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark. Svendsen ML, Gammelager H, Sværke C, Yong M, Chia VM, Christiansen CF, Fryzek JP, Clin Epidemiol 2013 5 97 103 23576882
4. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Tubiana-hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, Pion JM, Switsers O, Misset JL, Assadourian S, Bessa E, Bull Cancer 2001 88 701 707 11495824 (Pubitemid 32831138)
5. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. CH V p, Temin S, Yee GC, Janjan N, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, JH V r, J Clin Oncol 2011 29 1221 1227 10.1200/JCO.2010.32.5209 21343561
6. Bisphosphonates in the management of postmenopausal osteoporosis- optimizing efficacy in clinical practice. Bock O, Felsenberg D, Clin Interv Aging 2008 3 279 297 18686751 (Pubitemid 352037868)
7. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. Hershman DL, Mcmahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E, J Clin Oncol 2008 26 4739 4745 10.1200/JCO.2008.16.4707 18711172
8. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY, Breast Cancer Res Treat 2011 125 99 106 10.1007/s10549-010-1201-8 20922564
9. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E, Eur J Cancer 2011 47 683 689 10.1016/j.ejca.2010.11.024 21324674
10. Austrian Breast and Colorectal Cancer Study Group, Coleman RM. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Gnant M, Mlineritsch B, Luschin-ebengreuth G, Kainberger F, Kässmann H, Piswanger-sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, Lancet Oncol 2008 9 840 849 10.1016/S1470-2045(08) 70204-3 18718815
11. Bisphosphonates: preclinical review. Green JR, Oncologist 2004 9 3 13 (Pubitemid 39363164)
12. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C, Br J Cancer 2003 88 1631 1640 10.1038/sj.bjc.6600925 12771933 (Pubitemid 36713793)
13. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G, Nat Clin Pract Oncol 2006 3 325 338 10.1038/ncponc0520 16757970 (Pubitemid 43871543)
14. Breast-cancer adjuvant therapy with zoledronic acid. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R, Azure I, Van der vliet HM, N Engl J Med 2011 365 1396 1405 10.1056/NEJMoa1105195 21995387
15. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Gnant M, Mlineritsch B, Stoeger H, Luschin-ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria, Lancet Oncol 2011 12 631 641 10.1016/S1470-2045(11)70122-X 21641868
16. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Coleman R, De Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, Von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N, Ann Oncol 2013 24 398 405 10.1093/annonc/mds277 23047045
17. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast Cancer patients receiving letrozole. Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-aviles E, Hohneker J, Ericson SG, Perez EA, Adv Cancer Res 2012 118 1192 1201
18. Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. Aft RL, Naughton M, Trinkaus K, Weilbaecher K, Br J Cancer 2012 107 7 11 10.1038/bjc.2012.210 22617128
19. Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast Cancer. Leal T, Tevaarwerk A, Love R, Stewart J, Binkley N, Eickhoff J, Parrot B, Mulkerin D, Clin Breast Cancer 2010 10 471 476 10.3816/CBC.2010.n.062 21147691
20. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow up. Breast Cancer Symposium. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P, 2009 abstract n.213 http://meetinglibrary.asco.org/content/40178-70
21. Fukunaga Masao. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 36-month results. ASCO Annual Meeting. Takahashi S, Iwase T, Kohno N, Ishikawa T, Seung JK, Hosoda M, Horiguchi J, Yamauchi H, Hozumi Y, Okada M, 2013 abstract n.e20510 http://meetinglibrary.asco.org/content/110904-132
22. Immediate administration of zoledronic acid reduces aromatase Inhibitor-Associated bone loss in postmenopausal women with early breast Cancer: 12-month analysis of the E-ZO-FAST trial. Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P, Clin Breast Cancer 2012 12 40 48 10.1016/j.clbc.2011.08.002 22014381
23. Efficacy of zoledronic acid in postmenopausal Japanese women with early breast Cancer receiving adjuvant letrozole: 12-month results. Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, Horiguchi J, Nakamura S, Hozumi Y, Fukunaga M, Noguchi S, Breast Cancer Res Treat 2012 133 685 693 10.1007/s10549-012-1973-0 22307266
24. Oral adjuvant clodronate therapy could improve overall survival in early breast Cancer: Results from an updated systematic review and meta-analysis. Zhu J, Zheng Y, Zhou Z, Eur J Cancer 2013 959 00081 00084
25. Influence of zoledronic acid on disseminated tumor cells in primary breast Cancer patients. Solomayer EF, Gebauer G, Hirnle P, Janni W, Lück HJ, Becker S, Huober J, Krämer B, Wackwitz B, Wallwiener D, Fehm T, Ann Oncol 2012 23 2271 2277 10.1093/annonc/mdr612 22383680
26. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast Cancer: an open label, randomised, phase 2 trial. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-macgregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K, Lancet Oncol 2010 11 421 428 10.1016/S1470-2045(10)70054-1 20362507
27. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in Cancer patients in vivo. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A, Blood 2003 102 2310 2311 10.1182/blood-2003-05-1655 12959943 (Pubitemid 37122416)
28. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T, Clin Cancer Res 2004 10 4559 4567 10.1158/1078-0432.CCR-03-0325 15240548 (Pubitemid 38878900)
29. AD(2013),Phase III Randomized Study of Adjuvant Zoledronate versus Clodronate versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast (SWOG-S0307). Gralow J, Livingston R, Curr Contr Trials http://www.cancer.gov/clinicaltrials/featured/trials/swog-s0307
30. Rack B, Schindlbeck C, Andergassen U, Lorenz R, Zwingers T, Schneeweiss A, Lichtenegger W, Beckmann MW, Sommer H, Pantel K, Friese K, Janni W, Simultaneous Study of Docetaxel-Gemcitabine Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial (SUCCESS) San Antonio Breast Cancer Symposium-Cancer Therapy and Research Center at UT Health Schience Center 2010 8-12 December
31. Oral clodronate for adjuvant treatment of operable breast Cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N, Lancet Oncol 2012 13 734 742 10.1016/S1470-2045(12)70226-7 22704583
32. The efficacy of zoledronic acid in breast Cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Yan T, Yin W, Zhou Q, Zhou L, Jiang Y, Du Y, Shao Z, Lu J, Eur J Cancer 2012 48 187 195 22100904
33. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri D, Oncologist 2013 18 353 361 10.1634/theoncologist.2012-0261 23404816
34. Quantifying heterogeneity in a meta-analysis. Higgins JP, Thompson SG, Stat Med 2002 21 1539 1558 10.1002/sim.1186 12111919 (Pubitemid 34746062)
35. The combination of estimates from different experiments. Cochran WG, Biometrics 1954 10 101 129 10.2307/3001666